Kiadis Pharma Announces Investor Events for September 2019
19 Agosto 2019 - 12:45PM
Kiadis Pharma Announces Investor Events for September 2019
Company announces Notice of
Results for the six months ended June 30, 2019
Amsterdam, The Netherlands, August 19,
2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”)
(Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, announces its investor events in
September 2019.
Interim resultsKiadis will be
issuing its interim results for the six months ended June 30, 2019
at 7.00am CEST / 6.00am BST / 1.00am EDT on Tuesday, September 10,
2019.
Kiadis’ management will host a webcast and
conference call for analysts on Tuesday, September 10, 2019 at
3.00pm CEST / 2.00pm BST / 9.00am EDT. A copy of the announcement
will be made available on the Kiadis Pharma website and details of
the webcast and conference call will be made available within the
Investor section of the company website. The webcast will be
recorded, and a replay will be made available.
In addition, members of the Kiadis management
team will attend the following investor events in September:
Hot in HealthcareSeptember 19,
2019, Amsterdam, The NetherlandsKiadis will be participating in
one-on-one meetings with investors on 19 September.
KBC Annual Healthcare
ConferenceSeptember 26, 2019, Brussels, BelgiumKiadis will
be participating in one-on-one meetings with investors on 26
September.
Kiadis Contacts:
Kiadis
Pharma:Maryann Cimino, Manager, Corporate AffairsTel: +1
(617) 710-7305m.cimino@kiadis.com |
Optimum
Strategic Communications:Mary Clark, Supriya Mathur,
Hollie VileTel: +44 203 950 9144David Brilleslijper (Amsterdam)Tel:
+31 610 942 514kiadis@optimumcomms.com |
About Kiadis PharmaFounded in
1997, Kiadis Pharma, is a fully integrated biopharmaceutical
company committed to developing innovative therapies for patients
with late-stage blood cancers. With headquarters in Amsterdam, the
Netherlands, and offices in the US and across Europe, Kiadis Pharma
is leveraging the natural strengths of humanity and our collective
immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Forward Looking
StatementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma’s
or, as appropriate, Kiadis Pharma’s directors’ current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither Kiadis Pharma nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.